Treatment

Updated results from the phase 1a FIT-001 trial show that darlifarnib (KO-2806) combined with cabozantinib produced encouraging results in patients with advanced clear cell renal cell carcinoma (ccRCC) who had not previously received cabozantinib. The overall response rate ranged from 33% to 50% across the dose groups, and the median progression-free survival was 13 months. […]

A phase 3 study of cretostimogene grenadenorepvec showed encouraging results in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). The treatment produced a complete response in 75.5% of patients at some point during the study. The responses were long-lasting, with a median duration of at least 27.9 months. More

The final 10-year results from the phase 3 RELEVANCE trial show that the chemotherapy-free combination of lenalidomide plus rituximab (R²) provides long-term outcomes similar to standard immunochemotherapy for patients with previously untreated advanced follicular lymphoma. The study included 1,030 adults and followed them for a median of nearly 10 years. Patients treated with R² had

Top-line results from the phase 3 KEYNOTE-C93 trial showed that pembrolizumab (Keytruda) alone significantly improved progression-free survival compared with standard carboplatin and paclitaxel chemotherapy in patients with mismatch repair-deficient (dMMR) advanced or recurrent endometrial cancer. The study enrolled 299 patients who had not received prior systemic chemotherapy. A positive trend in overall survival was also

The phase 3 KEYNOTE-C93 trial showed that pembrolizumab (Keytruda) is more effective than standard chemotherapy as a first-line treatment for patients with advanced or recurrent mismatch repair-deficient (dMMR) endometrial cancer. The study included 299 patients who had not received previous chemotherapy for advanced disease or whose cancer returned more than six months after adjuvant treatment.

The phase 3 ARTEMIS-008 trial found that risvutatug rezetecan (Ris-Rez), an investigational antibody-drug conjugate (ADC), significantly improved overall survival compared with standard chemotherapy (topotecan) in patients with advanced or relapsed small cell lung cancer (SCLC). The study met its primary goal, making Ris-Rez the first B7-H3-targeted ADC to show a survival benefit in a phase

A phase 2 clinical trial led by the Dana-Farber Cancer Institute found that a three-drug combination produced high remission rates in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and aggressive blood cancer. The results were published in Blood. The study enrolled 27 patients with a median age of 70. Treatment combined tagraxofusp,

The phase 2 AZUR-1 trial has met its main goal, showing that dostarlimab (Jemperli) alone can produce a lasting complete response in patients with stage II/III dMMR/MSI-H locally advanced rectal cancer. An interim analysis found that many patients had no detectable signs of cancer 12 months or longer after starting treatment. The results suggest that

New data show that zoldonrasib (RMC-9805), an oral RAS G12D-targeted therapy, produced promising results in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) carrying a RAS G12D mutation. In previously untreated patients, zoldonrasib combined with modified FOLFIRINOX achieved an objective response rate of 82%, while the combination with gemcitabine plus nab-paclitaxel reached 61%. Disease control rates

New data suggest that the survival benefit of DCVax-L for patients with glioblastoma (GBM) is greater than previously reported. The original phase 3 analysis showed that DCVax-L improved median overall survival by 2.8 months. However, a new analysis using individual patient data from three randomized clinical trials found that the actual survival benefit ranged from